Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Elevated Triglycerides Clear all
Completed Phase 3 Interventional Results available

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

NCT01408303
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Disease
Interventions
Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
89
States / cities
Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

NCT01148004
View directory record Official record
Conditions
HIV, Fenofibrate, Protease Inhibitors, Hypertriglyceridemia, Glucuronosyltransferase
Interventions
Fenofibrate, Ritonavir, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 9, 2026, 9:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of Foods on Bile Acids, Metabolites, and Inflammation

NCT05245357
View directory record Official record
Conditions
Inflammation, Hypertriglyceridemia, Metabolic Disease, Lipid Metabolism Disorder, Hyperlipidemias, Bile Acid Malabsorption
Interventions
Lentil, Control
Behavioral
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Lapaquistat acetate and fenofibrate, Fenofibrate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

NCT00046267
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Diabetes Mellitus
Interventions
Niacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

NCT00246376
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis
Interventions
Diet, Exercise, Niacin, Fenofibrate, Placebos
Behavioral · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

NCT02639286
View directory record Official record
Conditions
Lipodystrophy
Interventions
ISIS 304801, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

NCT02250105
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
ARI-3037MO, Placebo
Drug
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

NCT01675154
View directory record Official record
Conditions
Type 1 Hyperlipoproteinemia
Interventions
SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

NCT02300233
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Volanesorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encinitas, California • San Francisco, California • Boca Raton, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

NCT00833976
View directory record Official record
Conditions
High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Lovaza
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 9:06 AM EDT
Withdrawn Phase 4 Interventional

Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients

NCT00397358
View directory record Official record
Conditions
Peritoneal Dialysis, Hypertriglyceridemia
Interventions
Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution
Drug
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Santa Clara, California • Michigan City, Indiana • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Leptin to Treat Lipodystrophy

NCT00025883
View directory record Official record
Conditions
Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Aronia on Inflammation and the Gut Microbiome

NCT04128839
View directory record Official record
Conditions
Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions
Aronia berry juice, Sham comparator
Dietary Supplement · Other
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 9, 2026, 9:06 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT06347003
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Garden Grove, California • Lake Forest, California • Montclair, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

NCT03398005
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 9, 2026, 9:06 AM EDT
Completed No phase listed Observational

The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients

NCT00001102
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

NCT00134498
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
39
States / cities
Anaheim, California • Huntington Beach, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Sep 9, 2026, 9:06 AM EDT
Not listed No phase listed Observational

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

NCT01086163
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Omacor, omega-3 fatty acids in CAD patients
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
50 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

NCT00812955
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
ABT-143, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
129
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Pentoxifylline Treatment in Acute Pancreatitis (AP)

NCT02487225
View directory record Official record
Conditions
Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis, Hypertriglyceridemia Acute Pancreatitis, Idiopathic (Unknown) Acute Pancreatitis, Medication Induced Acute Pancreatitis, Cancer Acute Pancreatitis, Miscellaneous (i.e. Acute on Chronic Pancreatitis)
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 9, 2026, 9:06 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Lovaza Mechanisms of Action

NCT01301794
View directory record Official record
Conditions
Moderate Hypertriglyceridemia.
Interventions
Omega 3 fatty acid (Lovaza)
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 9, 2026, 9:06 AM EDT